Helen Torley is PRESIDENT AND CEO of HALOZYME THERAPEUTICS, INC.. Currently has a direct ownership of 723,364 shares of HALO, which is worth approximately $41.8 Million. The most recent transaction as insider was on Feb 16, 2025, when has been sold 59,068 shares (Common Stock) at a price of $58.29 per share, resulting in proceeds of $3,443,073. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 723K
6.89% 3M change
6.89% 12M change
Total Value Held $41.8 Million

Helen Torley Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 16 2025
SELL
Payment of exercise price or tax liability
$3,443,073 $58.29 p/Share
59,068 Reduced 7.55%
723,364 Common Stock
Feb 16 2025
BUY
Exercise of conversion of derivative security
-
109,694 Added 13.03%
732,451 Common Stock
Feb 15 2025
SELL
Payment of exercise price or tax liability
$413,742 $58.29 p/Share
7,098 Reduced 1.04%
672,738 Common Stock
Feb 15 2025
BUY
Exercise of conversion of derivative security
-
13,092 Added 1.89%
679,836 Common Stock
Nov 29 2024
SELL
Bona fide gift
-
10,000 Reduced 1.48%
666,744 Common Stock
Oct 09 2024
SELL
Open market or private sale
$530,200 $53.02 p/Share
10,000 Reduced 1.46%
676,744 Common Stock
Oct 09 2024
BUY
Exercise of conversion of derivative security
$138,700 $13.87 p/Share
10,000 Added 1.44%
686,744 Common Stock
Oct 08 2024
SELL
Open market or private sale
$542,500 $54.25 p/Share
10,000 Reduced 1.46%
676,744 Common Stock
Oct 08 2024
BUY
Exercise of conversion of derivative security
$138,700 $13.87 p/Share
10,000 Added 1.44%
686,744 Common Stock
Sep 26 2024
SELL
Open market or private sale
$561,000 $56.1 p/Share
10,000 Reduced 1.46%
676,744 Common Stock
Sep 26 2024
BUY
Exercise of conversion of derivative security
$138,700 $13.87 p/Share
10,000 Added 1.44%
686,744 Common Stock
Sep 25 2024
SELL
Open market or private sale
$563,400 $56.34 p/Share
10,000 Reduced 1.46%
676,744 Common Stock
Sep 25 2024
BUY
Exercise of conversion of derivative security
$138,700 $13.87 p/Share
10,000 Added 1.44%
686,744 Common Stock
Sep 24 2024
SELL
Open market or private sale
$582,100 $58.21 p/Share
10,000 Reduced 1.46%
676,744 Common Stock
Sep 24 2024
BUY
Exercise of conversion of derivative security
$138,700 $13.87 p/Share
10,000 Added 1.44%
686,744 Common Stock
Sep 12 2024
SELL
Open market or private sale
$592,000 $59.2 p/Share
10,000 Reduced 1.46%
676,744 Common Stock
Sep 12 2024
BUY
Exercise of conversion of derivative security
$138,700 $13.87 p/Share
10,000 Added 1.44%
686,744 Common Stock
Sep 11 2024
SELL
Open market or private sale
$590,900 $59.09 p/Share
10,000 Reduced 1.46%
676,744 Common Stock
Sep 11 2024
BUY
Exercise of conversion of derivative security
$138,700 $13.87 p/Share
10,000 Added 1.44%
686,744 Common Stock
Sep 10 2024
SELL
Open market or private sale
$590,900 $59.09 p/Share
10,000 Reduced 1.46%
676,744 Common Stock
Sep 10 2024
BUY
Exercise of conversion of derivative security
$138,700 $13.87 p/Share
10,000 Added 1.44%
686,744 Common Stock
Aug 15 2024
SELL
Open market or private sale
$579,500 $57.95 p/Share
10,000 Reduced 1.46%
676,744 Common Stock
Aug 15 2024
BUY
Exercise of conversion of derivative security
$138,700 $13.87 p/Share
10,000 Added 1.44%
686,744 Common Stock
Aug 14 2024
SELL
Open market or private sale
$573,700 $57.37 p/Share
10,000 Reduced 1.46%
676,744 Common Stock
Aug 14 2024
BUY
Exercise of conversion of derivative security
$138,700 $13.87 p/Share
10,000 Added 1.44%
686,744 Common Stock

Also insider at

DGX
QUEST DIAGNOSTICS INC Healthcare
HT

Helen Torley

PRESIDENT AND CEO
Secaucus, NJ

Track Institutional and Insider Activities on HALO

Follow HALOZYME THERAPEUTICS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HALO shares.

Notify only if

Insider Trading

Get notified when an Halozyme Therapeutics, Inc. insider buys or sells HALO shares.

Notify only if

News

Receive news related to HALOZYME THERAPEUTICS, INC.

Track Activities on HALO